Bearish Risk: Rising Chemical Costs Choke Indian API Makers; Granules, Divi's Lab Under Pressure
Analyzing: “Rising costs of key chemicals choke production at drug ingredient makers” by et_companies · 25 Mar 2026, 12:52 AM IST (about 1 month ago)
What happened
Indian bulk-drug manufacturers are grappling with a severe cost crisis due to a sharp increase in prices of key solvents and intermediates. This surge is attributed to supply chain disruptions stemming from the West Asia conflict, leading to production halts for some units and a more than doubling of paracetamol API prices.
Why it matters
This situation is critical for the Indian pharmaceutical sector, which relies heavily on APIs and intermediates. Increased input costs will directly impact the profitability and margins of API manufacturers, potentially leading to higher drug prices for consumers and affecting the competitiveness of Indian pharma exports. The ripple effect could be felt across the entire drug manufacturing value chain.
Impact on Indian markets
API-focused pharmaceutical companies like Divi's Laboratories (DIVISLAB), Laurus Labs (LAURUSLABS), Granules India (GRANULES), IPCA Laboratories (IPCALAB), and Aurobindo Pharma (AUROPHARMA) are likely to face negative impacts due to higher raw material costs and potential production disruptions. This could lead to margin contraction and downward pressure on their stock prices. Companies with strong backward integration or long-term supply contracts might be relatively less affected.
What traders should watch next
Traders should closely monitor the upcoming quarterly results of API and bulk drug manufacturers for signs of margin erosion and commentary on input cost trends. Further escalation or de-escalation of the West Asia conflict will be crucial for supply chain stability. Also, watch for any government interventions or policy changes to support the domestic API industry.
Key Evidence
- •India's bulk-drug manufacturers face severe cost crisis.
- •Prices of key solvents and intermediates have surged due to West Asia conflict.
- •Supply disruptions linked to the conflict are causing the price increases.
- •Production halts reported for several units.
- •Paracetamol API prices have more than doubled.
- •The entire pharmaceutical value chain is impacted.
Affected Stocks
Major API manufacturer, susceptible to rising input costs and supply chain disruptions.
Significant API and intermediate manufacturer, vulnerable to increased raw material costs.
Key player in paracetamol API and formulations, directly impacted by paracetamol API price surge and input cost inflation.
Involved in API manufacturing, likely to face margin pressure from rising chemical costs.
Large API and formulation player, exposed to higher input costs for bulk drugs.
Sources and updates
AI-powered analysis by
Anadi Algo News